Metabolic reprogramming and synergistic cytotoxicity of genistein and chemotherapy in human breast cancer cells
Authors:
- Sandra Tobón-CornejoSTSandra Tobón-Cornejo
- Ariana Vargas-CastilloAVAriana Vargas-Castillo
- Mandy JuarezMJMandy Juarez
- Joshua Ayork Acevedo-CarabantesJAJoshua Ayork Acevedo-Carabantes
- Lilia G. NoriegaLNLilia G. Noriega
- Omar Granados-PortilloOGOmar Granados-Portillo
- Alma Chávez-BlancoACAlma Chávez-Blanco
- Rocío Morales-BárcenasRMRocío Morales-Bárcenas
- Nimbe TorresNimbe Torres
- Armando R. TovarATArmando R. Tovar
- Alejandro Schcolnik-CabreraASAlejandro Schcolnik-Cabrera
Preprint
Abstract
Breast cancer (BCa) is a heterogeneous disease, initially responsive to hormone therapy but often developing resistance to both hormonal and chemotherapy treatments. Novel therapeutic strategies are needed for drug-resistant BCa. Genistein, a phytoestrogen structurally similar to estrogen, competes with estrogen for receptor binding and exhibits anti-cancer effects. In this study, we investigated the cellular and metabolic impacts of genistein, alone or in combination with chemotherapy, in two human BCa cell lines—one estrogen receptor-positive (ER+) and one estrogen receptor-negative (ER−). We observed a strong synergistic effect on cell viability at low concentrations of genistein and chemotherapy, resulting in reduced clonogenic capacity and impaired cell migration. Genistein alone modulated cellular energy metabolism, notably reducing ATP production in MCF7 (ER+) cells. This metabolic shift was linked to a decreased dependence on fatty acids for energy, coupled with a decrease in the rate-limiting mitochondrial translocase CPT1 required for fatty acid oxidation, alongside with an increase in intracellular fatty acid levels. While the most significant changes occurred in ER+ cells, ER− cells also showed responses to genistein treatment. Collectively, our findings suggest that low dose genistein, in combination with conventional chemotherapy, induces synergistic anti-cancer effects, promoting cellular senescence. This effect may be partly mediated by a reduced reliance on fatty acid metabolism in BCa cells.Keywords
All Related Versions
- Published version: Life Sciences, 370, 123562.
This publication has 56 references indexed in Scilit:
- Genistein and coumestrol reduce MCF-7 breast cancer cell viability and inhibit markers of preferential metastasis, bone matrix attachment and tumor-induced osteoclastogenesisArchives of Biochemistry and Biophysics, 2023
- Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drugCancer Chemotherapy and Pharmacology, 2020
- Chemotherapy Use, Performance Status, and Quality of Life at the End of LifeJAMA Oncology, 2015
- A simple protocol for amino acid type selective isotope labeling in insect cells with improved yields and high reproducibilityJournal of Biomolecular NMR, 2011
- Soy Food Intake and Breast Cancer SurvivalJAMA, 2009
- Cancer is a Preventable Disease that Requires Major Lifestyle ChangesPharmaceutical Research, 2008
- Effect of genistein on cholesterol metabolism-related genes in a colon cancer cell lineGenes & Nutrition, 2008
- Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cellsEndocrine, 2007
- Expression of Bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2′-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicinCancer Chemotherapy and Pharmacology, 1998
- Lipid content and fatty acid composition of heart and muscle of the BIO 82.62 cardiomyopathic hamsterLipids, 1976